These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 26491974)

  • 1. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
    Cohen AD; Comenzo RL
    Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights and modern treatment of AL amyloidosis.
    Chaulagain CP; Comenzo RL
    Curr Hematol Malig Rep; 2013 Dec; 8(4):291-8. PubMed ID: 24026941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing systemic light-chain amyloidosis.
    Comenzo RL
    J Natl Compr Canc Netw; 2007 Feb; 5(2):179-87. PubMed ID: 17335687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Light chain (AL) amyloidosis: update on diagnosis and management.
    Rosenzweig M; Landau H
    J Hematol Oncol; 2011 Nov; 4():47. PubMed ID: 22100031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future directions in the clinical management of amyloid light-chain amyloidosis.
    Haider S; Ahmad N; Anaissie E; Driscoll JJ
    Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.
    D'Souza A; Huang J; Hari P
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):768-770. PubMed ID: 26743343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amyloid light chain amyloidosis].
    Suzuki K; Shimizu T
    Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How we treat systemic light-chain amyloidosis.
    Chaulagain CP; Comenzo RL
    Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.
    Vaxman I; Gertz M
    Acta Haematol; 2019; 141(2):93-106. PubMed ID: 30650422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
    Bellotti V; Mangione P; Merlini G
    J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
    Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
    Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.
    Mejhert M; Hast R; Sandstedt B; Janczewska I
    BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.